HC Wainwright Reaffirms “Buy” Rating for BioNTech (NASDAQ:BNTX)

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a report issued on Wednesday morning, Benzinga reports. They currently have a $107.00 price objective on the stock.

A number of other research analysts also recently issued reports on BNTX. The Goldman Sachs Group cut their price objective on BioNTech from $113.00 to $100.00 and set a neutral rating for the company in a research note on Wednesday, February 28th. Canaccord Genuity Group reiterated a buy rating and set a $171.00 price objective on shares of BioNTech in a research note on Thursday, March 21st. Oppenheimer began coverage on BioNTech in a research note on Friday, January 5th. They set a market perform rating for the company. UBS Group cut their price objective on BioNTech from $110.00 to $101.00 and set a neutral rating for the company in a research note on Wednesday, March 27th. Finally, JPMorgan Chase & Co. cut their price objective on BioNTech from $99.00 to $90.00 and set an underweight rating for the company in a research note on Friday, March 22nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech presently has an average rating of Hold and a consensus price target of $120.40.

BioNTech Trading Up 0.7 %

BioNTech stock opened at $86.81 on Wednesday. The business has a 50-day simple moving average of $91.21 and a two-hundred day simple moving average of $97.31. The company has a market cap of $20.64 billion, a P/E ratio of 21.07 and a beta of 0.23. BioNTech has a 52-week low of $85.21 and a 52-week high of $125.83. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. Analysts predict that BioNTech will post -1.67 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Bamco Inc. NY raised its holdings in shares of BioNTech by 123.1% during the 3rd quarter. Bamco Inc. NY now owns 158,911 shares of the company’s stock worth $17,264,000 after acquiring an additional 87,686 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of BioNTech by 3,881.3% during the 4th quarter. Fifth Third Bancorp now owns 16,642 shares of the company’s stock worth $1,756,000 after acquiring an additional 16,224 shares in the last quarter. Mackenzie Financial Corp raised its holdings in shares of BioNTech by 86.5% during the 3rd quarter. Mackenzie Financial Corp now owns 5,131 shares of the company’s stock worth $558,000 after acquiring an additional 2,380 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of BioNTech by 41.6% during the 3rd quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock worth $52,595,000 after acquiring an additional 142,344 shares in the last quarter. Finally, Pathstone Family Office LLC purchased a new stake in shares of BioNTech during the 3rd quarter worth approximately $217,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.